Biogen’s Spinraza set to increase its chances to maintain a strong position in spinal muscular atrophy
On 8 January, Biogen announced that the first spinal muscular atrophy (SMA) patient had been treated in its Phase IV…
Latest Analysis
-
4 days
-
5 days
-
4 weeks
-
4 weeks
-
4 days
-
5 days
-
4 weeks
-
4 weeks
Teva and MedinCell Looking to Enter Increasingly Competitive LAI Schizophrenia Market
On January 7, Teva Pharmaceuticals and MedinCell announced positive results from their Phase III trial (RISE Study) evaluating mdc-IRM (risperidone)…
Latest News
View More
GSK and Vir Biotechnology to initiate NHS-backed Covid-19 trial
GlaxoSmithKline (GSK) and Vir Biotechnology have announced an agreement with the UK-based AGILE initiative to conduct Phase Ib/IIa clinical trial of a monoclonal antibody, VIR-7832,…
Lilly reports positive data from Alzheimer’s disease treatment trial
Eli Lilly and Company has reported that data from Phase II TRAILBLAZER-ALZ study of its investigational antibody, donanemab, showed a significant slowing of decline in…
NeuroRx, Relief and Quantum Leap to include Zyesami in Covid-19 trial
NeuroRx, Relief Therapeutics and the Quantum Leap Healthcare Collaborative have signed a clinical trial participation agreement to include Zyesami (RLF-100:…
Sputnik V Covid-19 vaccine meets endpoints in India trial
Dr. Reddy’s Laboratories has announced that the Phase II clinical trial of the Russia's Covid-19 vaccine Sputnik V met the…
Biogen’s Spinraza set to increase its chances to maintain a strong position in spinal muscular atrophy
On 8 January, Biogen announced that the first spinal muscular atrophy (SMA) patient had been treated in its Phase IV…
Teva and MedinCell Looking to Enter Increasingly Competitive LAI Schizophrenia Market
On January 7, Teva Pharmaceuticals and MedinCell announced positive results from their Phase III trial (RISE Study) evaluating mdc-IRM (risperidone)…
Latest Content
View More
Biogen’s aducanumab in AD unlikely to be well-covered by payers, with FDA approval prospects mixed
by William Newton in Texas. Biogen antibody aducanumab, if FDA-approved for mild Alzheimer’s disease (AD), will likely face significant barriers…
A case for streamlined RFIs in the pharmaceutical industry
By Francis Dumont, senior director, drug product supply external strategy, pharmaceutical sciences, Pfizer Inc. The pharmaceutical industry continues to leverage…
OpenClinica Featured in ‘In Depth’ Educational TV Series
OpenClinica is pleased to announce that it will be included in public television series In Depth, exhibiting its clinical trials…
ORGOVYX (relugolix) for the Treatment of Advanced Prostate Cancer
ORGOVYX™ (relugolix) is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of advanced prostate…
EVERSANA and Experic Partner for Life Sciences Industry Manufacturing and Commercialisation
EVERSANA™ and Experic are pleased to announce that they will be partnering to aid life sciences companies in optimising clinical…
The Experic Difference for Dry Powder Inhalation
When you need customised and scalable filling, packaging and logistics solutions for reservoir and single-dose dry powder inhalation (DPI) devices,…